Chronic Thromboembolic Pulmonary Hypertension Clinical Trial
Official title:
An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
This is an open-label, single-armed, prospective single-centre clinical study to evaluate the effect of riociguat on right heart size and function in patients with manifest PAH and CTEPH.
Right heart size and function are of utmost prognostic importance in PAH/CTEPH. RV performance measured by echocardiography and enlarged RA area have been shown to be independent prognostic factors in PAH. Recently, a retrospective single centre study has shown that riociguat treatment was associated with a significant reduction of RV and RA area after 3, 6 and 12 months compared to baseline. RA area significantly decreased after 12 months and RV systolic function assessed with tricuspid annular plane systolic excursion (TAPSE) improved after 6 and 12 months of riociguat therapy. The results were confirmed by a recent retrospective multicentre study. It is therefore reasonable to assume a beneficial effect of riociguat on right heart size and function. The primary efficacy endpoint in this study is the change in RV and RA area from baseline to 24 weeks. Treatment will be initiated and individually adjusted according to systolic blood pressure and tolerability. Patients who discontinue medication prematurely will be asked to continue with study assessments and perform study visits as outlined in the protocol. Medical examinations comprise medical history, physical examination, electrocardiogram (ECG), blood gas analyses, lung function tests, laboratory testing (including NT-proBNP), echocardiography at rest, and right heart catheterization (RHC) according to clinical practice of the PH centre. The prospective period of data collection comprises a 24-week study period a follow-up phase of about 30±7 days. Outcome (survival and transplant-free survival) of all patients will be assessed when the last patient has terminated his/her 24-week observation period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06003244 -
High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)
|
N/A | |
| Active, not recruiting |
NCT06092424 -
High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)
|
N/A | |
| Active, not recruiting |
NCT06072417 -
HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)
|
N/A | |
| Terminated |
NCT01953965 -
Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.
|
Phase 2 | |
| Recruiting |
NCT02061787 -
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
|
||
| Not yet recruiting |
NCT03102294 -
Inspiratory Muscle Training in Chronic Thromboembolic Pulmonary Hypertension
|
N/A | |
| Recruiting |
NCT04071327 -
Pulmonary Hypertension Association Registry
|
||
| Completed |
NCT00313222 -
Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
|
Phase 3 | |
| Recruiting |
NCT05311072 -
Change-a Multi-center Chronic Thromboembolic Pulmonary Hypertension （CTEPH） Database in China
|
||
| Recruiting |
NCT05340023 -
Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension
|
||
| Enrolling by invitation |
NCT05568927 -
Validation of SEARCH, a Novel Hierarchical Algorithm to Define Long-term Outcomes After Pulmonary Embolism
|
||
| Completed |
NCT03786367 -
Dyspnea in Chronic Thromboembolic Pulmonary Hypertension
|
||
| Recruiting |
NCT04081012 -
N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Chronic Thromboembolic Pulmonary Hypertension.
|
N/A | |
| Not yet recruiting |
NCT06384534 -
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
|
N/A | |
| Withdrawn |
NCT05693779 -
Exercise Therapy After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
|
N/A | |
| Not yet recruiting |
NCT02426203 -
3D Echocardiographic Assessment of RV Function in Patients Undergoing Pulmonary Endarterectomy
|
N/A | |
| Completed |
NCT02094001 -
Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH
|
Phase 2 | |
| Enrolling by invitation |
NCT03388476 -
Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension
|
||
| Recruiting |
NCT04206852 -
Safety and Efficacy of Balloon Pulmonary Angioplasty in China
|
||
| Completed |
NCT02111980 -
RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators
|
N/A |